Biological E. Limited
11 articles with Biological E. Limited
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
Biological E to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX™
Texas Children's Hospital Center for Vaccine Development COVID-19 Subunit Vaccine Candidate Advancing Towards Global Access
Texas Children's Hospital and Baylor College of Medicine leading COVID-19 subunit vaccine candidate, developed with Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company, has received approval to proceed with Phase III clinical trials in India.
Biological E. Limited, Dynavax Technologies Corporation, and Baylor College of Medicine announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.
Takeda And Biological E. Limited Announce Partnership To Develop Low-Cost Combination Vaccines For Low- And Middle-Income Countries Around The Globe
VaxInnate Corporation Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine to Biological E. Limited; Vaccine Could Become Available for Use in India This Year
Biological E. Limited Strengthens Management Team with Appointment of Senior Vice Presidents from Leading Global Pharmaceutical and Biotech Firms
Biological E. Limited Names Experienced Biopharmaceutical Executive, Rayasam Prasad, as Chief Operating Officer for Global Biologics
Itero Biopharmaceuticals Inks Partnership With Indian Biotechnology Firm, Biological E. Limited; Raises $21 Million Venture Financing
Leading India Manufacturer Heparinex LLC and U.S. Companies Biological E. Limited and Choncept, LLC Sign Option/License Agreements